Cerebral edema in acute ischemic stroke patients treated with intravenous thrombolysis

被引:80
作者
Strbian, Daniel [1 ]
Meretoja, Atte [1 ]
Putaala, Jukka [1 ]
Kaste, Markku [1 ]
Tatlisumak, Turgut [1 ]
机构
[1] Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00290 Helsinki, Finland
关键词
brain swelling; cerebral edema; Ischemic stroke; outcome; thrombolysis; TISSUE-PLASMINOGEN ACTIVATOR; BRAIN EDEMA; ARTERY-OCCLUSION; CONTROLLED-TRIAL; ALTEPLASE; INFARCTION; REPERFUSION; THERAPY; PREDICTORS; ECASS;
D O I
10.1111/j.1747-4949.2012.00781.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Cerebral edema (CED) deteriorates outcome of ischemic stroke patients, and there is no effective medical treatment. Limited data exist on cerebral edema after stroke thrombolysis. Aims We aimed to analyze impact of cerebral edema on the outcome of thrombolysis-treated patients. Methods Our cohort included 943 thrombolysis-treated ischemic stroke patients at the Helsinki University Central Hospital (1995-2008). Cerebral edema represented focal brain swelling up to 1/3 (CED-1) or greater than 1/3 (CED-2) of the hemisphere, or midline shift (CED-3). We studied baseline parameters associated with development of cerebral edema and association of cerebral edema with three-month outcome (modified Rankin Scale, mRS). Results On control imaging, CED-1 was present in 167 (17 center dot 7%), CED-2 in 40 (4 center dot 2%), and CED-3 in 53 (5 center dot 6%) patients. Compared with patients without edema (n = 683), patients with cerebral edema had higher baseline National Institutes of Health Stroke Scale scores, more often hyperdense cerebral artery sign or early infarct signs on admission computerized tomography, and received thrombolysis later. Cerebral edema was independently associated with poor outcome (mRS 3-6) and mortality, whereas favorable outcome (mRS 0-2) was observed in 77 (46%), 5 (13%), and 3 (6%) patients with CED 1, 2, and 3, respectively. Anti-edema treatment was considered necessary and administered to 49/260 (19%) patients; only five had favorable outcome. Conclusions Cerebral edema is frequent (28%) among thrombolysis-treated ischemic stroke patients, occurring in severe forms in 10%. Higher baseline National Institutes of Health Stroke Scale, presence of hyperdense cerebral artery sign or early infarct signs, and longer treatment delays are associated with edema development. Edema is a strong independent predictor of three-month outcome. Effect of anti-edema treatment was modest.
引用
收藏
页码:529 / 534
页数:6
相关论文
共 28 条
[1]   Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].
Albers, GW ;
Bates, VE ;
Clark, WM ;
Bell, R ;
Verro, P ;
Hamilton, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150
[2]   Ischaemic brain oedema [J].
Ayata, C ;
Ropper, AH .
JOURNAL OF CLINICAL NEUROSCIENCE, 2002, 9 (02) :113-124
[3]   Antiedema therapy in ischemic stroke [J].
Bardutzky, Juergen ;
Schwab, Stefan .
STROKE, 2007, 38 (11) :3084-3094
[4]   Mannitol for acute stroke [J].
Bereczki, D. ;
Fekete, I ;
Prado, G. F. ;
Liu, M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03)
[5]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[6]   'Malignant' middle cerebral artery territory infarction - Clinical course and prognostic signs [J].
Hacke, W ;
Schwab, S ;
Horn, M ;
Spranger, M ;
DeGeorgia, M ;
vonKummer, R .
ARCHIVES OF NEUROLOGY, 1996, 53 (04) :309-315
[7]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[8]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[9]   Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J].
Hacke, Werner ;
Kaste, Markku ;
Bluhmki, Erich ;
Brozman, Miroslav ;
Davalos, Antoni ;
Guidetti, Donata ;
Larrue, Vincent ;
Lees, Kennedy R. ;
Medeghri, Zakaria ;
Machnig, Thomas ;
Schneider, Dietmar ;
von Kummer, Ruediger ;
Wahlgren, Nils ;
Toni, Danilo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1317-1329
[10]   Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study [J].
Hill, MD ;
Buchan, AM .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (10) :1307-1312